Human Investing’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-1,484
Closed -$207K 107
2026
Q1
$207K Buy
+1,484
New +$208K 0.03% 93
2025
Q4
Sell
-2,425
Closed -$269K 97
2025
Q3
$269K Buy
2,425
+6
+0.2% +$682 0.04% 80
2025
Q2
$268K Sell
2,419
-924
-28% -$98.3K 0.04% 79
2025
Q1
$375K Buy
3,343
+547
+20% +$56.4K 0.07% 66
2024
Q4
$258K Sell
2,796
-667
-19% -$60.1K 0.05% 83
2024
Q3
$290K Buy
3,463
+195
+6% +$14.9K 0.05% 80
2024
Q2
$224K Sell
3,268
-479
-13% -$32K 0.04% 86
2024
Q1
$274K Buy
3,747
+221
+6% +$17K 0.06% 78
2023
Q4
$286K Sell
3,526
-1,174
-25% -$91.4K 0.06% 79
2023
Q3
$352K Sell
4,700
-442
-9% -$34K 0.08% 75
2023
Q2
$396K Sell
5,142
-1,092
-18% -$87.1K 0.09% 73
2023
Q1
$517K Sell
6,234
-149
-2% -$12.3K 0.13% 65
2022
Q4
$548K Sell
6,383
-1,867
-23% -$148K 0.14% 68
2022
Q3
$509K Buy
8,250
+1,350
+20% +$85.1K 0.13% 85
2022
Q2
$426K Sell
6,900
-2,573
-27% -$159K 0.1% 97
2022
Q1
$563K Sell
9,473
-7,122
-43% -$455K 0.12% 95
2021
Q4
$1.21M Sell
16,595
-265
-2% -$18.3K 0.29% 52
2021
Q3
$1.18M Buy
16,860
+15
+0.1% +$1.05K 0.28% 57
2021
Q2
$1.16M Sell
16,845
-133
-0.8% -$8.88K 0.28% 63
2021
Q1
$1.1M Buy
16,978
+1,704
+11% +$110K 0.28% 63
2020
Q4
$890K Sell
15,274
-1,349
-8% -$81.4K 0.25% 86
2020
Q3
$1.05M Sell
16,623
-614
-4% -$42.6K 0.34% 73
2020
Q2
$1.33M Buy
17,237
+149
+0.9% +$11.4K 0.47% 53
2020
Q1
$1.28M Sell
17,088
-29,101
-63% -$2.01M 0.55% 45
2019
Q4
$3M Sell
46,189
-3,357
-7% -$219K 0.98% 18
2019
Q3
$3.14M Sell
49,546
-149
-0.3% -$9.74K 1.11% 15
2019
Q2
$3.36M Buy
49,695
+1,225
+3% +$80.6K 1.23% 13
2019
Q1
$3.15M Buy
48,470
+1,872
+4% +$124K 1.18% 16
2018
Q4
$2.92M Buy
+46,598
New +$3.26M 1.22% 15

Other funds holding GILD

Human Investing's GILD Position: Q2 2026 in Review

Human Investing sold out of Gilead Sciences (GILD) in Q2 2026, closing a stake of 1,484 shares — an estimated $207K sold.

Human Investing first reported a position in GILD in Q4 2018 and held it in 29 quarters. The position peaked at $3.36M in Q2 2019. 2,272 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Human Investing reported no remaining Gilead Sciences position as of Q2 2026 after selling out during the quarter.
  • Human Investing sold 1,484 Gilead Sciences shares in Q2 2026, an estimated $207K.
  • Human Investing first reported a position in Gilead Sciences in Q4 2018 and held it in 29 quarters.
  • Human Investing's Gilead Sciences position peaked at $3.36M in Q2 2019.
  • 2,272 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Human Investing's 13F filing for Q2 2026, filed 20 Jul 2026.